The human ether-a-go-go-related gene (hERG) current inhibition selectively prolongs action potential of midmyocardial

C Yasuda1, S Yasuda2, H Yamashita2

  • 1Department of Human and Engineered Environmental Studies, Graduate School of Frontier Sciences, The University of Tokyo, Chiba, Japan.

Insights

Drug-induced arrhythmias stem from prolonged action potential duration due to hERG channel inhibition. This study reveals disopyramide disproportionately lengthens M-cell action potentials, increasing repolarization dispersion and arrhythmogenesis risk.

Area of Science:

  • Cardiovascular Pharmacology
  • Cardiac Electrophysiology
  • Computational Biology

Background:

  • Drug-induced arrhythmias are a significant clinical concern.
  • Prolongation of action potential duration (APD) by hERG channel inhibition is a known risk factor.
  • Sustained arrhythmias require both APD prolongation and transmural dispersion of repolarization.

Purpose of the Study:

  • To investigate the effect of hERG inhibition on transmural dispersion of APD.
  • To elucidate the cellular mechanisms underlying drug-induced proarrhythmia.
  • To evaluate the utility of the action potential clamp technique in studying hERG-mediated arrhythmogenesis.

Main Methods:

  • Utilized the action potential clamp technique, integrating in silico myocyte models with experimental I(Kr) measurements.
  • Measured whole-cell I(Kr) in hERG-expressing cells.
  • Coupled experimental data with ventricular endocardial, M-, and epicardial cell models to simulate action potentials under control and disopyramide conditions.

Main Results:

  • Disopyramide dose-dependently increased APDs in all simulated cell types.
  • M-cell APD prolongation was disproportionate at higher disopyramide concentrations, leading to significant dispersion of repolarization.
  • Disopyramide's effects on peak I(Kr) and current-voltage relationships were similar across cell types, suggesting M-cell specific electrophysiological properties contribute to dispersion.

Conclusions:

  • Disopyramide induces significant transmural dispersion of repolarization by disproportionately affecting M-cells.
  • Reduced repolarization reserve in M-cells, potentially due to lower levels of other potassium currents, explains the observed dispersion.
  • The action potential clamp technique is a valuable tool for dissecting hERG inhibition-induced arrhythmogenesis via transmural repolarization dispersion.

Related Concept Videos

Cardiac Action Potential01:30

Cardiac Action Potential

Cardiac action potentials are essential for proper heart function, enabling the rhythmic contractions needed for adequate blood circulation. Nodal cells and Purkinje fibers, specialized for electrical conduction, generate these action potentials.
The cardiac action potential process involves a series of phases characterized by the movement of ions across the cardiac cell membranes, leading to the depolarization and repolarization of the cardiac myocytes.
Ionic Basis of Cardiac Action Potentials
9.3K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
3.0K
G-Protein Gated Ion Channels01:21

G-Protein Gated Ion Channels

GPCRs are primarily responsible for our sense of smell, taste, and vision.  The binding of a sensory stimulus activates GPCR to stimulate effector proteins, many of which are ion channels in the sensory organs. GPCRs modulate the opening and closing of the target ion channels either directly by binding them, or by releasing second messengers that activate these channels. As ions move across the membrane, the membrane potential is altered, which induces an appropriate response.
Sensory...
7.0K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
4.1K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.7K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.3K